Anesthesiology Research Analysis
Q1 2026 anesthesiology research coalesced around precision, biomarker-guided critical care and neuro-technologies that bridge mechanism to practice. Two Lancet Respiratory Medicine papers anchored a precision sepsis arc: a validated three-biomarker ML framework (DIP/cDIP) enabling stratified immunomodulation, and a Bayesian, biomarker-enriched phase 3 trial suggesting mortality reduction with polymyxin B hemoadsorption in endotoxic shock. Cross-species adversarial AI mapped mechanistic biomarker
Summary
Q1 2026 anesthesiology research coalesced around precision, biomarker-guided critical care and neuro-technologies that bridge mechanism to practice. Two Lancet Respiratory Medicine papers anchored a precision sepsis arc: a validated three-biomarker ML framework (DIP/cDIP) enabling stratified immunomodulation, and a Bayesian, biomarker-enriched phase 3 trial suggesting mortality reduction with polymyxin B hemoadsorption in endotoxic shock. Cross-species adversarial AI mapped mechanistic biomarkers and neuromodulation targets for disorders of consciousness, while a phase 4 RCT showed the G protein–biased μ-agonist oliceridine halves hypoxia during ambulatory gynecologic sedation. Foundational biology advanced through a neutrophil EGFR–MAPK14–CEBPβ–PGLYRP1–TREM1 circuit driving NETosis and endothelial protection via neutralizing truncated procalcitonin, complemented by nanoscale mitochondrial trafficking (Drp1/TNT) in septic myocardium and enteric glial connexin-43 as a perioperative ileus target. Together, these studies prioritize biomarker-enriched trials, safer sedation paradigms, and immunovascular therapeutics that can reshape perioperative critical care.
Selected Articles
1. Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial.
A multicohort analysis derived and externally validated a three-biomarker ML framework (procalcitonin, sTREM-1, IL-6) to quantify immune dysregulation (DIP/cDIP), linked to mortality and secondary infection; reanalysis of a hydrocortisone RCT suggested survival benefit confined to severely dysregulated patients.
Impact: Offers a validated, simple, and implementable tool to reduce treatment-effect heterogeneity in sepsis and to guide biomarker-stratified immunomodulation and trial design.
Clinical Implications: Measuring PCT, sTREM-1, and IL-6 can support precision allocation of corticosteroids or other immunomodulators and enable biomarker-stratified trials in pneumonia/sepsis.
Key Findings
- A 3-biomarker model (PCT, sTREM-1, IL-6) achieved high accuracy for immune dysregulation (DIP 91.2%; cDIP RMSE 0.056).
- Higher cDIP independently associated with increased mortality and secondary infections.
- Hydrocortisone RCT reanalysis showed survival benefit only in severe dysregulation (e.g., cDIP ≥0.63).
2. EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction.
A translational mechanistic study mapped an EGFR–MAPK14–CEBPβ–PGLYRP1–TREM1 circuit in neutrophils that drives pathological NETosis and organ injury in sepsis; neutrophil-specific EGFR deletion mitigated cytokine storm, NETs, tissue damage, and improved survival in mice.
Impact: Defines a druggable neutrophil-intrinsic signaling axis linking receptor activation to NETosis, providing concrete targets (EGFR, MAPK14, PGLYRP1/TREM-1) for sepsis immunomodulation.
Clinical Implications: Enables target selection and biomarker-based stratification in sepsis trials (e.g., EGFR/PGLYRP1 expression), supporting development of EGFR modulators and TREM‑1 inhibitors.
Key Findings
- Neutrophil EGFR is upregulated in sepsis and correlates with severity.
- Neutrophil-specific EGFR knockout reduced cytokine storm, NETs, tissue injury, and improved survival in polymicrobial sepsis models.
- EGFR→MAPK14→CEBPβ drives PGLYRP1 transcription; PGLYRP1 amplifies NETosis via autocrine TREM-1 signaling.
3. Molecular architecture of human dermal sleeping nociceptors.
Patch‑seq and cross‑species transcriptomics identified OSMR and SST as markers of mechano‑insensitive C‑fiber nociceptors, with oncostatin M selectively modulating these fibers in human volunteers, defining a targetable human nociceptor subtype for neuropathic‑pain interventions.
Impact: Establishes a human, targetable nociceptor subtype with translational human modulation, enabling biomarker‑driven analgesic development and patient stratification.
Clinical Implications: Supports development of agents or neuromodulation targeting OSMR/SST‑expressing nociceptors; may inform perioperative neuropathic pain prevention and chronic pain management.
Key Findings
- OSMR and SST are marker genes for mechano‑insensitive C‑fiber nociceptors (CMis).
- Oncostatin M selectively modulates CMis in human volunteers.
- Cross‑species transcriptomics aligned human and animal CMis phenotypes.
4. Adversarial AI reveals mechanisms and treatments for disorders of consciousness.
A generative adversarial AI trained on >680,000 neuroelectrophysiology samples reproduced cross-species signatures of consciousness vs coma, generated testable mechanistic predictions (e.g., indirect basal ganglia pathway disruption, enhanced inhibitory-to-inhibitory coupling), and highlighted subthalamic nucleus high-frequency stimulation as a candidate intervention.
Impact: Links interpretable AI with causal mechanistic hypotheses and neuromodulation targets, bridging neuroscience, anesthesiology, and critical care to enable targeted trials and refined monitoring.
Clinical Implications: Provides mechanistic biomarkers and a plausible target (subthalamic nucleus stimulation) for prospective neuromodulation studies and informs development of next-generation perioperative consciousness monitors.
Key Findings
- Modeled consciousness vs coma across species using >680,000 10-second electrophysiology samples and validated in 565 human/animal datasets.
- Predicted basal ganglia indirect pathway disruption and increased cortical inhibitory-to-inhibitory coupling, supported by diffusion MRI and RNA-seq/animal data.
- Identified subthalamic nucleus high-frequency stimulation as a promising therapeutic target.
5. Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial.
A biomarker-enriched Bayesian phase 3 RCT (n=157) in vasopressor-dependent septic shock with high endotoxin activity showed high posterior probabilities of reduced 28- and 90-day mortality with two sessions of polymyxin B hemoadsorption added to standard care, with acceptable safety.
Impact: Delivers the strongest randomized evidence to date for an endotoxin-targeted extracorporeal therapy in a rigorously phenotyped septic shock subgroup, advancing precision critical care.
Clinical Implications: Consider polymyxin B hemoadsorption as an adjunct in vasopressor-dependent septic shock with endotoxin activity 0.60–0.89 and multiorgan failure, using strict selection, monitoring, and outcome auditing while awaiting larger pragmatic trials.
Key Findings
- Biomarker-enriched enrollment targeted high endotoxin activity (0.60–0.89) in vasopressor-dependent septic shock (n=157).
- 28-day mortality was lower with hemoadsorption (posterior probability of benefit 95.3%; adjusted OR 0.67; 95% CrI 0.39–1.08).
- 90-day posterior probability of benefit was 99.4% (adjusted OR 0.54; 95% CrI 0.32–0.87).
6. Cytoskeletal remodeling promotes tunneling nanotube formation and drives cardiac resident cell mitochondrial transfer in sepsis.
Using a CLP sepsis model with single-cell transcriptomics, the study shows Drp1-driven cytoskeletal remodeling orchestrates TNT biogenesis and long-range mitochondrial trafficking in cardiac cells; cardiac-specific Drp1 knockout disrupts TNT-mediated exchange and halts metabolic deterioration, nominating Drp1/TNT as a therapeutic axis.
Impact: Reveals a nanoscale organelle-transfer mechanism linking cytoskeletal remodeling to metabolic failure in septic myocardium, opening a tractable molecular target.
Clinical Implications: Targeting Drp1/TNT-mediated mitochondrial exchange could become a novel approach to prevent or mitigate septic cardiomyopathy; requires human tissue validation and pharmacologic modulation studies.
Key Findings
- Drp1-driven cytoskeletal remodeling orchestrates TNT biogenesis enabling mitochondrial trafficking across cardiac cell types.
- Cardiac-specific Drp1 knockout disrupts TNT-mediated mitochondrial exchange and halts metabolic deterioration.
- Single-cell transcriptomics in CLP sepsis mapped TNT-related gene programs and metabolic reprogramming across cardiac cells.
7. Glial Connexin-43 is a pathogenic mechanism promoting gut inflammation after postsurgical intestinal manipulation with potential relevance to humans.
This translational study identifies enteric glial connexin‑43 as a highly expressed, surgery‑upregulated hemichannel driving enteric gliosis, immune activation, inflammation, and neuropathy underlying postoperative ileus. Glial‑specific deletion and the peptide inhibitor 43Gap26 attenuated pro‑inflammatory signaling and POI features in mice, with supportive expression patterns in human surgical tissues and human enteric glia.
Impact: Defines a tractable, cell‑specific signaling node that links surgical trauma to POI across species, creating a clear pathway to peptide or small‑molecule hemichannel modulators for perioperative organ‑protection trials.
Clinical Implications: Supports development of selective Cx43 hemichannel modulators and perioperative trials incorporating enteric gliosis/inflammation biomarkers to prevent POI in high‑risk abdominal surgery.
Key Findings
- Cx43 is the predominant connexin in enteric glia (mouse and human) and is upregulated after surgical manipulation.
- Glial‑specific Cx43 deletion mitigated glial reactivity, pro‑inflammatory signaling, immune activation, and prevented enteric neuropathy in a mouse POI model.
- IL‑1β opens Cx43 hemichannels in human enteric glia to increase IL‑6/CCL2 release; 43Gap26 blocks these responses; human surgical samples showed concordant Cx43 upregulation.
8. Effect of Neostigmine on Attenuation of Proinflammatory Cytokines When Given as an Adjuvant Therapy in Septic Shock: A Randomized Control Trial.
A double‑blind randomized trial showed that continuous low‑dose neostigmine (0.2 mg/hr for 5 days) significantly reduced TNF‑α at day 5, improved SOFA trajectories, and decreased 28‑day mortality (26% vs 54%) in septic shock, supporting augmentation of the cholinergic anti‑inflammatory pathway as adjunctive therapy.
Impact: Delivers randomized evidence of a mortality benefit using an inexpensive, widely available drug via a defined immunomodulatory mechanism—practice‑changing potential if replicated.
Clinical Implications: Pending multicenter replication, protocols may consider neostigmine infusion as an adjunct in septic shock while closely monitoring hemodynamics and anticholinesterase effects.
Key Findings
- Day‑5 TNF‑α was significantly lower with neostigmine (40±36 vs 67±43 pg/mL; p=0.002).
- SOFA trajectories improved in the neostigmine arm.
- 28‑day mortality decreased (26% vs 54%; p=0.02).
9. Effect of oliceridine on hypoxia during sedated hysteroscopy: a Phase 4 randomized clinical trial.
In a double-blind randomized trial (n=492) of ambulatory gynecologic sedation, oliceridine (a G protein–biased μ-agonist) halved intraoperative hypoxia versus sufentanil, raised nadir SpO2, and reduced supplemental propofol requirements, indicating improved respiratory safety.
Impact: Provides large, pragmatic, blinded evidence that a biased μ-agonist can meaningfully improve respiratory safety during procedural sedation—directly informing opioid selection.
Clinical Implications: Consider oliceridine as an alternative to conventional potent opioids for ambulatory procedural sedation protocols to reduce hypoxia risk, while accounting for availability, monitoring standards, and cost.
Key Findings
- Randomized, double-blind comparison of oliceridine vs sufentanil during sedated hysteroscopy (n=492).
- Intraoperative hypoxia incidence: 9.8% (oliceridine) vs 19.5% (sufentanil); RR 0.50 (95% CI 0.32–0.79; P=0.002).
- Higher nadir SpO2 and reduced supplemental propofol needs with oliceridine.
10. Endothelial cell responses in sepsis are attenuated by targeting truncated procalcitonin.
Neutralizing truncated procalcitonin preserved endothelial barrier function, mitigated vasoplegia, maintained endothelial NO bioavailability, and improved organ-level outcomes in sepsis models, reducing >50% of endothelial transcriptomic perturbations and dampening IL‑17 pathway signaling.
Impact: Links a widely measured clinical biomarker to a druggable endothelial-protective mechanism, opening a translational path for vascular-focused sepsis therapy.
Clinical Implications: Supports development of anti‑procalcitonin biologics to preserve endothelial integrity and reduce vasoplegia in septic shock; next steps include pharmacology, large‑animal safety, and early human studies.
Key Findings
- Anti-procalcitonin reduced endothelial transcriptomic changes by >50% and preserved lung/intestinal barriers.
- Mitigated vasoplegia and preserved endothelial NO bioavailability, improving organ integrity.
- Mechanistically associated with reduced IL‑17 pathway signaling in sepsis.